Last reviewed · How we verify
Oral quinine
Oral quinine, marketed by Makerere University, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the credibility of Makerere University. The primary risk is the lack of disclosed revenue and key trial results, which may limit investor confidence and competitive positioning.
At a glance
| Generic name | Oral quinine |
|---|---|
| Sponsor | Makerere University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease (PHASE2)
- Mass Screening and Treatment for Reduction of Falciparum Malaria (NA)
- Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
- Studies on the Impact of Taste-aware Intelligent Analysis of Oral Nutritional Supplements
- Post-discharge Malaria Chemoprevention(PMC) Study (PHASE3)
- Quinine and Food Intake (NA)
- Effect of Bitter in Overweight Female Volunteers (PHASE4)
- Effect of Hydroxychloroquine Sulphate in Healthy Lean Females (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral quinine CI brief — competitive landscape report
- Oral quinine updates RSS · CI watch RSS
- Makerere University portfolio CI